Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

If you have metastatic non-small-cell lungcancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in ...

Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

80% of lung cancer is something called nonsmall cell lung cancer. So where are we today in terms of diagnosis, treatment, and what does the future hold? So to help answer these questions ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

Real-world experiences and treatments for lung cancer and head & neck cancer were shared at scientific conferences entitled ...